Enox Biopharma

Nitric Oxide Embedding for Medical Devices

Health Tech & Life Sciences
Non Active, Oct 2020 ceased to operate

Company Overview

Snapshot

Founded in April 2007 by Dan Sadeh Hochstadter and Yossef Av-Gay, Enox Biopharma operates with 1–10 employees. The company focuses on medical device innovation and received a European patent for its 'Device and Method for Administering Therapeutic Agents' in June 2011.

Business overview

Enox Biopharma is a biotechnology company specializing in proprietary technology that embeds nitric oxide (NO) into polymer-based medical devices to render them antimicrobial. The company has developed a method for impregnating polymer-based devices with NO, ensuring its extended release at levels effective against microbes. Enox Biopharma's product development targets devices frequently associated with high infection rates, such as urinary catheters, endotracheal tubes, central venous catheters, and tympanostomy tubes, operating within the Health Tech & Life Sciences sector, specifically focusing on Medical Devices and Material Innovations & Applications.

Strategic signal

In June 2011, Enox Biopharma secured a European patent for its 'Device and Method for Administering Therapeutic Agents'. This patent validated the company's innovative approach to embedding nitric oxide into medical devices, signaling a significant intellectual property milestone and potential for market differentiation in the antimicrobial medical device sector.

Company Intelligence Q&A

What is Enox Biopharma's core technology?
Enox Biopharma's core technology involves embedding nitric oxide (NO) into polymer-based medical devices to provide antimicrobial properties, releasing NO over extended periods to prevent infections.
When was Enox Biopharma founded and by whom?
Enox Biopharma was founded in April 2007 by Dan Sadeh Hochstadter and Yossef Av-Gay.
What types of medical devices does Enox Biopharma target?
Enox Biopharma focuses on devices such as urinary catheters, endotracheal tubes, central venous catheters, and tympanostomy tubes, which are temporary inserts often associated with high infection rates.
What was a significant intellectual property milestone for Enox Biopharma?
In June 2011, Enox Biopharma received a European patent for its 'Device and Method for Administering Therapeutic Agents'.
What is the current status of Enox Biopharma?
Enox Biopharma is currently non-active, having ceased operations in October 2020.

External links